Showing results (111-120 of 170) with videos related to
Sort By:
Pageof 17
Journal of Medical Internet Research|September 11, 2020
Artificial Intelligence and Its Effect on Dermatologists' Accuracy in Dermoscopic Melanoma Image Classification: Web-Based Survey StudyRoman C Maron, Jochen S Utikal, Achim Hekler, et al.Journal of Neuro-Oncology|January 9, 2016
Targeted next generation sequencing reveals unique mutation profile of primary melanocytic tumors of the central nervous systemJohannes van de Nes, Marco Gessi, Antje Sucker, et al.European Journal of Cancer (Oxford, England : 1990)|February 8, 2017
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patientsKilian Wistuba-Hamprecht, Alexander Martens, Florian Heubach, et al.Nature Communications|June 1, 2017
Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesionsAntje Sucker, Fang Zhao, Natalia Pieper, et al.Cancer Immunology, Immunotherapy : CII|February 27, 2019
First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysisBastian Schilling, Alexander Martens, Marnix H Geukes Foppen, et al.European Journal of Cancer (Oxford, England : 1990)|July 12, 2016
Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumabKilian Wistuba-Hamprecht, Alexander Martens, Karin Haehnel, et al.Nature Communications|May 21, 2025
Dermatologist-like explainable AI enhances melanoma diagnosis accuracy: eye-tracking studyTirtha Chanda, Sarah Haggenmueller, Tabea-Clara Bucher, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|November 26, 2022
Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre studyAlexander Thiem, Pegah Mashhadiakbar, Christiane Cussigh, et al.Lancet (London, England)|May 18, 2020
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, et al.Cancers|June 2, 2021
Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma PatientsGeorg Lodde, Andrea Forschner, Jessica Hassel, et al.Pageof 17